New Orleans-Transrectal ultrasound-guided biopsy of the prostate appears to have an immediate impact on the semen parameters of reproductive-age men, according to findings from a small study from Beth Israel Medical Center, New York. However, these effects were transient in all but one patient.
Las Vegas-In a recent trial, men with erectile dysfunction and their partners reported that they were somewhat satisfied with a new wrap-around prosthetic device used to stiffen the men's penises.
Las Vegas-Middle-aged men with erectile dysfunction may benefit from penile microvascular arterial bypass surgery as much as young men do, Boston University researchers reported at the Sexual Medicine Society of North America fall meeting here.
Las Vegas-An investigational drug that acts on the central nervous system may work as a treatment for female sexual dysfunction (FSD), according to a recent study from New York Presbyterian Hospital/Weill Cornell Medical Center in New York. The drug, bremelanotide, is also being investigated for the treatment of erectile dysfunction in men.
Las Vegas-Most men with erectile dysfunction should be tested for androgen deficiency, according to researchers from the University of Minnesota Medical School, Minneapolis. In their study of men with erectile dysfunction, nearly half had testosterone levels less than 400 ng/dL, but they cautioned that the results did not suggest a cause-effect relationship.
New York-Management of metastatic, clear-cell renal cell carcinoma has been significantly advanced by the development of the oral small-molecule kinase inhibitors sunitinib malate (Sutent) and sorafenib (Nexavar), recent results from two large, international, randomized, double-blind, phase III trials indicate. Both studies appeared in the Jan. 11, 2007 issue of the New England Journal of Medicine (2007; 356:115-24 and 125-34).
Patients should be advised that ED is a good possibility with any form of treatment.
Highlights of an industry-sponsored educational program at the 24th World Congress of Endourology. The 24th World Congress of Endourology was jointly sponsored by The Cleveland Clinic Center for Continuing Education and the Endourological Society and was held on The Cleveland Clinic campus in Ohio, August 17?20, 2006.
HealthTronics, Inc., an Austin, TX-based provider of services and products for the urology community, has entered into a definitive agreement for the purchase of a 35% interest in Keystone Mobile Partners, LP, Willow Grove, PA.
Bostwick Laboratories, which provides pathology and diagnostic laboratory services in the United States and United Kingdom, has opened a new laboratory in Uniondale, NY. Separately, Hillel Kahane, MD, has been appointed medical director of the new facility, the company’s fifth.
The manufacturer of a sexual performance-enhancing supplement has announced a voluntary recall of the product, known as Liviro3. FDA lab analysis found the product contains the erectile dysfunction drug tadalafil, making Liviro3 an unapproved drug.
Circulating tumor cell levels 3 to 5 weeks after the initiation of chemotherapy appear to predict overall survival in patients with metastatic androgen-independent prostate cancer, according to a prospective multicenter trial. Further, overall survival could be predicted at each of the tested time points.
Researchers at Northwestern University’s Feinberg School of Medicine, Chicago, have discovered that men who have had a vasectomy may be at increased risk for developing primary progressive aphasia (PPA), an irreversible neurologic disorder that causes patients to lose the ability to use and comprehend words.
Erectile dysfunction is significantly and independently associated with age, cardiovascular disease, diabetes, and lack of physical activity, suggests a study published in The American Journal of Medicine (2007; 120:151-7). Using data obtained from a computerized self-interview, the authors found that 18.4% of men 20 years of age and older experienced ED, defined as “sometimes able” or “never able” to have and keep an erection.
Obese men are more likely than are normal-weight men to have a prostate cancer screening, and associations among advanced stage, worse outcomes, and obesity may not be explained by disparities in screening, according to a study published in the Journal of Urology (2007; 177:493-8).
GPC Biotech AG has completed its rolling submission of a new drug application to the FDA for its oral formulation of satraplatin for the treatment of patients with androgen-independent prostate cancer who have failed prior chemotherapy.
David L. Murray, 72, of Naples, FL, who formed the publishing company that originally published Urology Times, passed away Jan. 31, 2007.
Verathon, Inc. (Bothell, WA) has issued a challenge to urology researchers: The company is offering $10,000 for the most practical and scientifically valid protocol to study the relationship of bladder wall mass and overactive bladder or BPH. The goal is to determine how bladder wall mass measurements can best be used in clinical practice.
A set of molecular biomarkers might predict the recurrence of bladder cancer and survival from the disease better than conventional prognostic features, University of Texas Southwestern Medical Center, Dallas, researchers have found. Once a patient undergoes radical cystectomy, researchers say a routine tissue analysis could easily test for the presence of altered proteins that they found to help ascertain the chances that the cancer will return.
A new study from the University of Michigan Health System establishes one of the strongest connections yet discovered between muscle damage that can occur during vaginal deliveries and pelvic organ prolapse, the authors say.
The National Comprehensive Cancer Network (NCCN) has updated its prostate cancer guidelines, which now include revised recommendations regarding pelvic lymph node dissection, robotics, and the use of bisphosphonate therapy.
The FDA has approved new labeling for sunitinib malate (Sutent) to include first-line treatment of advanced renal cell carcinoma. The labeling change is based on results of a large phase III trial that showed prolonged progression-free survival.
More than 90% of men who receive appropriate radiation dose levels with permanent radiation seed implants to treat their prostate cancer are cured of the disease 8 years after diagnosis, according to a recent study in the International Journal for Radiation Oncology Biology Physics (2007; 67:327-33).
Higher levels of a protein made by a gene known as JM-27 have been found in men whose BPH is more severe and more likely to lead to bladder-related complications if left untreated, according to Johns Hopkins researchers. The team, lead by Robert Getzenberg, PhD, also developed a blood test that detects the JM-27 protein in men with severe symptoms.
images
Herbal supplements and other complementary therapies are surrounded by clinical and ethical issues, some involving urologists.
Atlanta-Secondary testicular ascent (acquired cryptorchidism) remains a relatively rare condition, occurring in 3.2% to 6.9% of patients in a recent cohort study of boys with retractile testes. The diagnosis of ascent is becoming more commonplace, and ,therefore, boys with questionable testicular exams should have follow-up through adolescence, according to re-searchers from the Vanderbilt University Children's Hospital, Nashville, TN.
Postoperative hemorrhage can and will occur in a minority of patients, despite the most careful of laparoscopic procedures.